GlassScriptPhysician profile
Jonathan R Diamond
NPI 1578539433
$248,985.95
in general payments reported to CMS, 2019-2025
33 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $26K · 2021: $27K · 2022: $57K · 2023: $13K · 2024: $45K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Food and Beverage: $10K · Travel and Lodging: $7,626 · Consulting Fee: $2,838 · Education: $133 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,615.50 |
| Food and Beverage | $10,049.29 |
| Travel and Lodging | $7,626.30 |
| Consulting Fee | $2,838.00 |
| Education | $132.83 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $105,494.45 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $87,219.85 | 2021-2025 | |
| Mallinckrodt Enterprises LLC | $33,224.27 | 2019 | |
| Akebia Therapeutics INC | $8,647.57 | 2019-2024 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $2,865.74 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $1,289.92 | 2019-2025 | Tavneos, Uplizna, Krystexxa |
| Vifor Pharma, INC. | $1,105.36 | 2020-2025 | Veltassa, Korsuva |
| Ani Pharmaceuticals, INC. | $1,083.49 | 2022-2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $1,029.59 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $992.63 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $815.15 | 2022-2025 | Filspari |
| Fresenius USA Marketing, INC. | $734.84 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Ardelyx, INC. | $717.92 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Glaxosmithkline, LLC. | $606.83 | 2020-2025 | Benlysta, Jesduvroq, Arexvy |
| Calliditas Therapeutics US INC. | $537.54 | 2023-2025 | Tarpeyo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $526.94 | 2021-2025 | Lupkynis |
| Daiichi Sankyo INC. | $449.23 | 2019-2022 | |
| Novo Nordisk INC | $267.76 | 2024-2025 | Rivfloza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $265.74 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.72 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $181.69 | 2025 | |
| Novartis Pharmaceuticals Corporation | $159.07 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $140.23 | 2021-2023 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $103.60 | 2022 | |
| Genzyme Corporation | $101.38 | 2021-2024 | |
| Lilly USA, LLC | $53.36 | 2023-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $36.60 | 2022 | |
| Tersera Therapeutics LLC | $32.06 | 2024 | Quzyttir |
| Apellis Pharmaceuticals, INC. | $26.33 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $23.50 | 2021 | |
| Horizon Therapeutics Plc | $21.34 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.82 | 2021 | |
| Baxter Healthcare | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.